Pfizer Q3 2026 Earnings: Oncology and New Products

Pfizer (PFE) reports Q3 2026 results today with shares near a 52-week high as investors weigh newer-product growth, oncology gains and a looming patent cliff.

Lead

What Is Pfizer Expected to Report?

Pfizer is expected to report a year-on-year drop in both earnings and revenue, driven mainly by the collapse of its COVID-19 products. In the second quarter, Paxlovid sales fell 95% operationally and Comirnaty fell 34%. Revenue that quarter was $15.0 billion, up 3% as reported and 1% operationally, with adjusted EPS of $0.77, flat on the year and ahead of the $0.68 consensus.

Excluding COVID products, second-quarter revenue grew 5% operationally. Launched and acquired products rose 18%. The company has beaten consensus EPS in each of the last eight quarters, though estimates have slipped about 4% over 30 days and 10% over 90 days, which lowers the bar for today's print.

Why Are Pfizer Shares Near a 52-Week High?

Pfizer shares sit near a 52-week high because the second-quarter beat, a higher revenue outlook and cost cuts have shifted the debate from COVID decline to pipeline delivery. The stock closed at $30.52 on Oct. 30, up 1.9% on volume of about 45.5 million shares, its heaviest in weeks. The 52-week range is $23.62 to $30.67. The shares have gained roughly 10% in one month and 22% over three months, lifting market capitalization to about $174 billion.

Management raised the midpoint of 2026 revenue guidance by $500 million in August, to $60.5-$62.5 billion. Adjusted EPS guidance of $2.80-$3.00 was reaffirmed, absorbing about $0.10 of dilution from the $650 million Innovent Biologics deal. Pfizer also announced $2.5 billion of additional productivity savings for 2027-2029 and expanded its manufacturing optimization program to target $1.5 billion in savings through 2029. The dividend yield is near 5.8%, which draws income investors.

Which Products Drive Pfizer's Oncology Growth?

Pfizer's oncology growth is led by Padcev, Lorbrena and the Braftovi-Mektovi combination, which are offsetting erosion in older cancer drugs. In the second quarter, Padcev rose 23% operationally and Lorbrena 37%. Eliquis, the anticoagulant, rose 19% and the Vyndaqel family 8%.

Ibrance and Adcetris are expected to decline again. The Padcev label was expanded by the FDA this year, and Phase 3 data for Talzenna in prostate cancer were positive. Investors will test whether the newer cancer franchises are growing fast enough to replace the older ones.

What Comes Next for Pfizer's Patent Cliff?

The key question is how Pfizer replaces revenue from Eliquis, Ibrance and Xtandi, all of which face loss of exclusivity in the coming years. Management has pointed to high single-digit growth in the long run, while consensus models imply little growth over the next decade. That gap is the central valuation question for the stock.

The obesity push is the main bridge. Pfizer closed its acquisition of Metsera on Nov. 13, 2025, at $65.60 per share in cash plus a contingent value right of up to $20.65 per share. The obesity candidate berobenatide advanced in Phase 2 in the second quarter. Any update on timelines, dosing data or Phase 3 plans would carry weight today.

Market Reaction

Options pricing implies a move of about 3.8%, or roughly $1.16 per share, in either direction after the report. With the shares just under their 52-week high, a guidance reaffirmation without a raise could be read as a pause. A higher revenue range or faster cost progress could push the stock through $30.67.

Outlook

Pfizer enters the quarter with a lowered consensus bar, a strengthening oncology portfolio and a stock near its yearly peak. Today's focus areas are the full-year guidance, the pace of savings, newer-product growth, and clarity on obesity development. The longer-term test remains whether launched and acquired products can offset the patent expirations ahead.